Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Recent & Breaking News (TSXV:ARCH)

Arch Biopartners Forms Clinical and Medical Advisory Board for AB569

MarketWire Canada July 18, 2016

Arch "Borg" Peptide Coating Displays Anti Corrosion Performance on Stainless Steel

MarketWire Canada July 5, 2016

Arch Biopartners Closes First Tranche of Private Placement

MarketWire Canada June 23, 2016

Arch Biopartners Announces Non Brokered Private Placement Financing

MarketWire Canada June 14, 2016

Arch Biopartners' AB569 Receives Final Approval from European Commission for Orphan Designation for Cystic Fibrosis

MarketWire Canada June 1, 2016

Arch Biopartners' AB569 Receives Positive Opinion from EMA COMP for Orphan Designation for Cystic Fibrosis

Marketwired April 26, 2016

Arch Biopartners Enters Exclusive License Agreement With University of Cincinnati for AB569

Marketwired March 16, 2016

Arch Scientists Publish Data on the Efficacy and Mechanism of Action of Lead Drug Candidate AB569

Marketwired March 1, 2016

Arch Biopartners Submits Orphan Drug Application for AB569 to European Medicines Agency

Marketwired February 3, 2016

Arch Biopartners, McMaster Scientists, Expand MetaMx Collaboration with Mitacs Award

Marketwired January 6, 2016

Arch Biopartners Provides MetaMx Development Update

Marketwired December 1, 2015

Arch Biopartners Receives Orphan Drug Designation from FDA for AB569

Marketwired November 13, 2015

Arch Biopartners Retains Virtus Advisory to Provide Investor Relations Services

Marketwired October 21, 2015

Arch Biopartners: AB569 Successfully Completes Pre-Clinical Validation Studies

Marketwired September 17, 2015

Arch Biopartners Announces Issuance of U.S. Patent for Brain Tumor Targeting Peptides

Marketwired August 5, 2015

Arch Biopartners Announces Issuance of a Second U.S. Patent for Peptide Solid Surface Interface

Marketwired August 4, 2015

Arch Biopartners Announces Issuance of a Second U.S. Patent for Peptide Solid Surface Interface

Marketwired August 4, 2015

Arch Scientists Use 'BORG' Peptides to Improve Biocompatibilty of Polysulfone for Use in Dialysis

Marketwired July 23, 2015

Dr. Sheila Singh, MD PhD. Joins Arch Biopartners as Medical and Clincial Advisor

Marketwired June 8, 2015

Arch Biopartners 2015 AGM Results and Technology Status Update

Marketwired April 1, 2015